Vaccine malosi fou e faasaga i le Omicron ma le lumana'i

A HOLD Fa'asa'oloto 5 | eTurboNews | eTN

O le Codagenix Inc., o se kamupani faʻataʻitaʻi faʻataʻitaʻi faʻataʻitaʻi faʻataʻitaʻi faʻatasi ma se faʻavae faʻataʻitaʻiga o tui faʻapitoa e faʻatatau i faʻamaʻi pipisi ma le kanesa, i aso nei na faʻasalalau faʻamaumauga le tumau Vaega 1 e faʻaalia ai le faʻaogaina o le T cell immunity faasaga i antigens sili ona puipuia o le SARS-CoV-2 Omicron variant pe a mae'a tui e lua o lana tui tui toto, CoviLiv (na ta'ua muamua Covi-Vac). O tagata matutua soifua maloloina na faʻaalia le faʻateleina o tali puipuia o sela T, e mafua mai i polotini e le o ni spike lea e tulaga ese i totonu o CoviLiv o se siama faʻamaʻi ola, e faʻaalia ai le ono mafai ona puipuia mai le puipuiga i le tele o popolega.           

O faʻamatalaga muamua mai le Vaega 1 faʻataʻitaʻiga na tuʻuina atu ile IDWeek ia Oketopa 2021 na faʻaalia ai o le tui intranasal CoviLiv na maua ai se tali malosi (IgG) antibody faʻapea foʻi ma le faʻaosoina o le mucosal immunity i le isu, ma le 40% o tagata auai na tuʻuina atu anti-COVID Immunoglobulin A ( IgA) antibodies. O faʻamatalaga lata mai na faʻasalalau i aso nei na iloilo ai le tali atu i le telefoni feaveaʻi aʻo leʻi faia ma ina ua maeʻa le tui ma maua ai le sili atu i le fa faʻatupuina o tali i se vaitaele peptide e lima eseese SARS-CoV-2 polotini, e aofia ai ae le gata i le spike. O lo'o fa'ailoa mai ai o tali fa'aoso T cell e fa'apitoa i polotini e le-spike, lea e matua fa'asaoina i itu eseese o popolega. O le vaitaele peptide na suʻeina e> 99.2% tutusa ma le Omicron strain BA.2.

Fa'amaumauga atoa o le Vaega 1 CoviLiv e fa'amoemoe ile ogatotonu ole 2022. Codagenix o loʻo faʻataunuʻuina le tulitatao mo lenei faʻataʻitaʻiga muamua i totonu o le tagata Vaega 1 (NCT04619628) ma o loʻo amataina se faʻataʻitaʻiga e faʻaaoga ai le CoviLiv o se faʻamalosia tele i tagata taʻitoʻatasi na faia muamua tui puipui faʻatagaina COVID-19 (NCT05233826). A'oa'o atili e uiga i nei su'esu'ega ile clinicaltrials.gov.

"O nei faʻamatalaga faʻamaonia e faʻaalia ai e mafai e CoviLiv ona tuʻuina atu se tali malosi e puipuia ai Omicron ma atonu o suiga i le lumanaʻi e aunoa ma le manaʻomia e toe faʻainisinia ituaiga eseese-faʻapitoa o le tui, e pei ona manaʻomia mo tui faʻapitoa. I le avea ai o se tui tui i totonu o le toto, o le CoviLiv e faʻaosofia ai le mucosal immunity, lea e fesoʻotaʻi ma le maualalo o faʻamaʻi pipisi ma faʻasalalauga ma faigofie ona faʻatinoina-o se mea taua tele mo le foia o pa puipui o tui puipui i le lalolagi atoa, "o le tala lea a J. Robert Coleman, Ph.D., MBA. , Fa'avae Fa'atasi ma le Ofisa Sili o le Codagenix. "O la matou faʻasalalauga biology faʻapipiʻi e mafai ai ona matou atiaʻe tui malosi ma faʻaoga lautele e faʻatatau i le atoaga o viral epitopes i lo latou tulaga faʻale-natura, e iʻu ai i tui e sili atu ona aoga ma saogalemu."

I le 2020, na ulufale atu ai Codagenix i se atinaʻe ma le gaosiga o faiga faapaaga ma le Serum Institute of India, o le kamupani sili ona tele o tui puipui i le lalolagi e ala i tui na gaosia ma faʻatau atu. O lenei faiga faapaaga o le a mafai ai e Codagenix ona maua le malosi o le gaosiga o le Serum Institute ma le tele o maketi faapisinisi i le lalolagi atoa.

OA MEA E AVEA MAI LENEI TUSI:

  • Previous data from the Phase 1 trial presented at IDWeek in October 2021 showed that the intranasal vaccine CoviLiv generated a robust serum (IgG) antibody response as well as induced mucosal immunity in the nose, with 40% of participants presenting anti-COVID Immunoglobulin A (IgA) antibodies.
  • Codagenix is in the process of completing follow-up for this first in-human Phase 1 trial (NCT04619628) and is commencing a trial using CoviLiv as a heterologous booster in individuals previously immunized with authorized COVID-19 vaccines (NCT05233826).
  • , a clinical-stage synthetic biology company with a rational vaccine design platform aimed at infectious diseases and cancer, today announced interim Phase 1 data indicating induction of T cell immunity against highly-conserved antigens of the SARS-CoV-2 Omicron variant following two doses of its intranasal vaccine, CoviLiv (previously called Covi-Vac).

<

E uiga i le tusitala

Linda Hohnholz

Faatonu sili mo eTurboNews fa'avae ile eTN HQ.

lesitala
Faasilasila i
mālō
0 faamatalaga
Manatu Faʻapena
Vaʻai manatu uma
0
E te alofa i ou mafaufauga, faamolemole taʻu mai.x
()
x
Fa'asoa i...